Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

Summary

To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.

Timeline

Start

2009-12

Primary completion

2012-10

Completion

2012-10

Outcome

Met primary endpoint

registry analysis (superiority or other test); Rasagiline 1 mg vs Placebo; p = 0.012; Mean Difference (Final Values) -2.4 (95% CI -4.3 to -0.5); ANCOVA; NCT01049984 ↗

release “a double-blind, placebo controlled, randomized, multicenter study of Azilect® (rasagiline tablets) met its primary endpoint. The study, known as ANDANTE” tevapharm.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rasagiline	Small molecule	1 mg	Oral

Indications